Why the study?
Type 1 diabetes is associated with excess cardiovascular risk beyond traditional risk factors, driving a need to identify metabolic contributors and evaluate whether cardioprotective type 2 diabetes medications reduce premature morbidity and mortality.
Do cardioprotective type 2 diabetes medications prevent premature morbidity and mortality in patients with type 1 diabetes?
Do cardioprotective type 2 diabetes medications prevent premature morbidity and mortality in patients with type 1 diabetes?
There is an urgent need to investigate whether cardioprotective medications used in type 2 diabetes can reduce the excess cardiovascular mortality seen in type 1 diabetes.
Answers are grounded in this paper and cite their sources.
Highlights urgent need to identify metabolic drivers of excess CV risk in T1D; leaves open whether T2D cardioprotective agents reduce mortality in this population.
Type 1 diabetes is associated with excess cardiovascular risk, even after accounting for traditional cardiovascular risk factors, including glycaemia. Hence, there is an urgent need to document the metabolic abnormalities that contribute to the cardiovascular mortality gap in type 1 diabetes, and to examine whether cardioprotective type 2 diabetes medications prevent premature morbidity and mortality in this population.
No takes yet. Share an insight, caveat, or question.
Greenfield et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: